How should clinicians and patients choose antihyperglycemic agents? An evidence-based approach

Victor M. Montori; James Deming; Nilay D. Shah

doi:10.20452/pamw.1059

How should clinicians and patients choose antihyperglycemic agents? An evidence-based approach

Victor M. Montori, James Deming, Nilay D. Shah

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

The choice of antihyperglycemic agents has become more complex as new drug classes have appeared and evidence about their efficacy and safety accumulates. Unfortunately, direct and fair comparisons are lacking and the clinician and patient are left to decide among agents with different safety and burden profiles. Furthermore, the relative efficacy of these agents beyond their ability to lower hemoglobin A_1c - that is, in their ability to reduce the risk of diabetes complications - remains uncertain. In this sea of uncertainty, interests other than those of the patient actively shape choices. It is our expectation that better evidence, better policy and better decisions will eventually become routine in the care of patients with diabetes. Copyright by Medycyna Praktyczna, 2011.

Original language	English (US)
Pages (from-to)	208-212
Number of pages	5
Journal	Polskie Archiwum Medycyny Wewnetrznej
Volume	121
Issue number	6
DOIs	https://doi.org/10.20452/pamw.1059
State	Published - 2011

Keywords

Antihyperglycemic agents
Clinical decision making
Patient-centered care
Type 2 diabetes

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.20452/pamw.1059

Cite this

@article{1b80f12a01494af3ba4c8a927586cb51,

title = "How should clinicians and patients choose antihyperglycemic agents? An evidence-based approach",

abstract = "The choice of antihyperglycemic agents has become more complex as new drug classes have appeared and evidence about their efficacy and safety accumulates. Unfortunately, direct and fair comparisons are lacking and the clinician and patient are left to decide among agents with different safety and burden profiles. Furthermore, the relative efficacy of these agents beyond their ability to lower hemoglobin A1c - that is, in their ability to reduce the risk of diabetes complications - remains uncertain. In this sea of uncertainty, interests other than those of the patient actively shape choices. It is our expectation that better evidence, better policy and better decisions will eventually become routine in the care of patients with diabetes. Copyright by Medycyna Praktyczna, 2011.",

keywords = "Antihyperglycemic agents, Clinical decision making, Patient-centered care, Type 2 diabetes",

author = "Montori, {Victor M.} and James Deming and Shah, {Nilay D.}",

year = "2011",

doi = "10.20452/pamw.1059",

language = "English (US)",

volume = "121",

pages = "208--212",

journal = "Polskie Archiwum Medycyny Wewnetrznej",

issn = "0032-3772",

publisher = "Medycyna Praktyczna",

number = "6",

}

TY - JOUR

T1 - How should clinicians and patients choose antihyperglycemic agents? An evidence-based approach

AU - Montori, Victor M.

AU - Deming, James

AU - Shah, Nilay D.

PY - 2011

Y1 - 2011

N2 - The choice of antihyperglycemic agents has become more complex as new drug classes have appeared and evidence about their efficacy and safety accumulates. Unfortunately, direct and fair comparisons are lacking and the clinician and patient are left to decide among agents with different safety and burden profiles. Furthermore, the relative efficacy of these agents beyond their ability to lower hemoglobin A1c - that is, in their ability to reduce the risk of diabetes complications - remains uncertain. In this sea of uncertainty, interests other than those of the patient actively shape choices. It is our expectation that better evidence, better policy and better decisions will eventually become routine in the care of patients with diabetes. Copyright by Medycyna Praktyczna, 2011.

AB - The choice of antihyperglycemic agents has become more complex as new drug classes have appeared and evidence about their efficacy and safety accumulates. Unfortunately, direct and fair comparisons are lacking and the clinician and patient are left to decide among agents with different safety and burden profiles. Furthermore, the relative efficacy of these agents beyond their ability to lower hemoglobin A1c - that is, in their ability to reduce the risk of diabetes complications - remains uncertain. In this sea of uncertainty, interests other than those of the patient actively shape choices. It is our expectation that better evidence, better policy and better decisions will eventually become routine in the care of patients with diabetes. Copyright by Medycyna Praktyczna, 2011.

KW - Antihyperglycemic agents

KW - Clinical decision making

KW - Patient-centered care

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=79959553833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959553833&partnerID=8YFLogxK

U2 - 10.20452/pamw.1059

DO - 10.20452/pamw.1059

M3 - Article

C2 - 21694685

AN - SCOPUS:79959553833

SN - 0032-3772

VL - 121

SP - 208

EP - 212

JO - Polskie Archiwum Medycyny Wewnetrznej

JF - Polskie Archiwum Medycyny Wewnetrznej

IS - 6

ER -

How should clinicians and patients choose antihyperglycemic agents? An evidence-based approach

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this